Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rechallenge Chemotherapy in 3rd+ Line mCRC
NCT03485027Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Started Jan 2018; status: completed.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03485027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03485027.